Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06578741 · ClinicalTrials.gov registry record · NA
GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis Post-Approval Study
A NA study, sponsored by W.L.Gore & Associates.
- Active
- Registry status
- NA
- Development phase
- 310
- Enrollment target
NCT06578741: Active NA study, sponsored by W.L.Gore & Associates.
NCT06578741 is a NA study that is active but no longer recruiting, run by W.L.Gore & Associates. The registered enrollment target is 310 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06578741, a NA study, is active but no longer recruiting, sponsored by W.L.Gore & Associates.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 310 participants
- Enrollment target
Study Summary
This study aims to confirm that the benefit-risk assessment of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device) remains positive in real-world use and to ensure the adequacy of the TAMBE Device training program.
Primary Outcome
All of the qualifying criteria are met (in the absence of surgical conversion or mortality, type I or type III endoleak, branch occlusion, or graft limb obstruction): * Successful access to the arterial system using remote arterial exposure, percutaneous technique, or open surgical conduits at index procedure. * Successful delivery and deployment of the aortic stent graft and all modular stent graft components at index procedure * Successful side branch catheterization and placement of bridging
Interventions
- DEVICE GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 310 participants |
| Start Date | 2024-11-25 |
| Est. Completion | 2036-06-01 |
| Phase | NA |
What the registry record for NCT06578741 still lists
NCT06578741 is an interventional study that assigns participants to a tested intervention. The registered 310 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (78% lower).
The record links to 0 conditions, and to 1 intervention - of which GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device) is the first listed.
NCT06578741 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06578741 about?
NCT06578741 is a clinical study titled "GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis Post-Approval Study". This study aims to confirm that the benefit-risk assessment of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device) remains positive in real-world use and to ensure the adequacy of the TAMBE Device training program.
What is the current status of trial NCT06578741?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 310 participants. The study started on 2024-11-25. Estimated completion is 2036-06-01.
What interventions are being tested in trial NCT06578741?
The interventions under investigation include: GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device) (DEVICE).
Who is sponsoring clinical trial NCT06578741?
This trial is sponsored by W.L.Gore & Associates, which has 53 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06578741's enrollment target sits among peer trials
310 323rd of 2000 higher than 1,678 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03039439 · 310 participants
Molecular and Immunohistochemical Profiling of Tumors in Patients With Parathyroid Tumors
- NCT04178018 · 310 participants · NA
Transvaginal Ultrasound and Photoacoustic Imaging of Ovary
- NCT04878094 · 310 participants · Phase 3
A Study of Intra-operative Imaging in Women With Ovarian Cancer
- NCT05459233 · 310 participants · NA
Valve Hemodynamic Optimization Based on Doppler-Echocardiography vs Catheterization Measurements Following ViV TAVR
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI